Glenmark Pharmaceuticals Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Get Glenmark Pharmaceuticals Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house.
quick-summary-circle
company-logo

Click to see a quick summary and important updates about this stock!Dismiss

Glenmark Pharmaceuticals Ltd.

BSE: 532296, NSE: GLENMARK

  • Market Capitalisation market-capitalisation-info ₹12,010 Cr

  • 12 Month Earnings monthly-earning ₹881 Cr
  • Price to Earnings price-to-earning 13.67

₹425.70

As on 24-Mar-2023 IST

up-down-arrow-11.05-2.53%

  • Prev Close info

    436.75

  • Day's Openinfo

    433.05

  • Today's Highinfo

    444.95

  • Today's Lowinfo

    423.95

  • Today's Volumeinfo

    10,94,792

Please wait...

Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Glenmark Pharmaceuticals
0.37 -5.02 -0.80 -6.18 31.29 -4.48 -1.31
S&P BSE Healthcare
-6.40 -1.75 -7.34 -11.05 25.12 10.47 10.49
S&P BSE Mid Cap
-6.64 -2.42 -3.25 -0.67 34.51 8.53 14.54
As on 24-Mar-2023
2022
2021
2020
2019
2018
2017
2016
Glenmark Pharmaceuticals
-19.75 5.16 42.75 -49.80 16.26 -33.06 -3.82
S&P BSE Mid Cap
1.38 39.18 19.87 -3.05 -13.31 48.13 7.97
S&P BSE Healthcare
-12.10 20.87 61.45 -3.55 -5.89 0.49 -12.88

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Glenmark Pharmaceuticals Ltd.

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        News & Analysis of Glenmark Pharmaceuticals Ltd.

        Incorporated

        1977

        Chairman

        Glenn Saldanha

        Managing Director

        Glenn Saldanha

        Group

        Glenmark

        Headquarters

        Mumbai, Maharashtra
        Edit peer-selector-edit
        Please wait...
        Please wait...
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information ₹12,010.49 Cr
        • Revenue (TTM)revenue-information ₹12,635.54 Cr
        • Earnings (TTM) earning-information ₹881.14 Cr
        • Cash date-information ₹1,240.04 Cr
        • Total Debt info ₹3,670.35 Cr
        • Promoters' ownership promoters_ownership 46.65%
        • Liquidity liquidity High
        • 52 Week range week-range ₹348.50 - 487.55
        • Face value face-value ₹1.00
        • Shares outstanding share-outstanding 28,21,68,156
        • 10 Years Aggregate:

          CFO: ₹9,590.11 Cr

          EBITDA: ₹16,098.16 Cr

          Net Profit: ₹7,703.74 Cr

        About The Company

        • Business Manufacture of allopathic pharmaceutical preparations
        • Incorporated 1977
        • Chairman Glenn Saldanha
        • Managing Director Glenn Saldanha
        • Group Glenmark
        • Listing key-listing BSE: 532296, NSE: GLENMARK
        • Country India
        • Headquarters headquarters Mumbai, Maharashtra
        • Website website www.glenmarkpharma.com